Active Ingredient(s): Fosdenopterin
FDA Approved: * February 26, 2021
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Nulibry Overview

Fosdenopterin (or cyclic pyranopterin monophosphate, cPMP), sold under the brand name Nulibry, is a medication used to reduce the risk of death due to a rare genetic disease known as molybdenum cofactor deficiency type A.[2] The most common side effects include complications related to the intravenous line, fever, respiratory infections, vomiting, gastroenteritis, and diarrhea.[2] Fosdenopterin was approved for medical use in the United States in February 2021....

Read more Nulibry Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Nulibry Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 9.5mg
  • Powder: 9.5mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Fosdenopterin or a similar ingredient: (1 result)